Unidad de Investigación Clínica de Cáncer de Mama

Miguel Angel Quintela Jefe de Unidad de Investigación Clínica
T +34 917328000 (Ext 2930)
mquintela@cnio.es

Investigadores

Becarios Post-doctorales

Rebeca Gema Jimeno
Ana María Roncero

Becarios Pre-Doctorales

José Luis Ruiz

Técnicos de Laboratorio

The Breast Cancer Clinical Research Unit (BCCRU) focuses on the translational interface of therapeutic development. Breast cancer is a heterogeneous disease and, thus, there are large inter-patient variations in terms of disease course, prognosis, relapse, and resistance to conventional or targeted therapeutics. Our activities are directed towards personalised treatment and range from preclinical models to correlative studies and clinical trials.

Our current research areas are:

Studying the implications of hypoxia for immunotherapies.
Understanding the individual factors regulating the response to immunotherapy in breast cancer, taking advantage of an advanced, personalised “tumouroid” platform.
Tackling the mechanisms of resistance against novel therapies in advanced breast cancer.
Incorporating our findings into concept-driven clinical trials.

Publicaciones

Mouron S, Bueno MJ, Lluch A, Manso L, Calvo I, Cortes J, Garcia-Saenz JA, Gil-Gil M, Martinez-Janez N, Apala JV, Caleiras E, Ximénez-Embún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo JM, Gómez-López G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M (2022). Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Nat Commun 13, 7529. Publicación CNIO.
Hühn D, Martí-Rodrigo P, Mouron S, Hansel C, Tschapalda K, Porebski B, Häggblad M, Lidemalm L, Quintela-Fandino M, Carreras-Puigvert J, Fernandez-Capetillo O. (2022). Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells. Mol Oncol 16, 148-165. Publicación CNIO. Open Access
Jimeno R, Mouron S, Salgado R, Loi S, Pérez-Mies B, Sánchez-Bayona R, Manso L, Martínez M, Garrido-García A, Serrano-Pardo R, Colomer R, Quintela-Fandino M (2022). Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer. Clin Transl Oncol (in press). Publicación CNIO.
Mestre-Farrera A, Bruch-Oms M, Peña R, Rodríguez-Morató J, Alba-Castellón L, Cormena L, Quintela-Fandino M, Duñach M, Baulida J, Pozo OJ, García de Herreros A (2021). Glutamine-Directed Migration of Cancer-Activated Fibroblasts Facilitates Epithelial Tumor Invasion. Cancer Res 81, 438-451. Publicación CNIO.
Luna-Dulcey L, Almada da Silva J, Jimenez-Renard V, Caleiras E, Mouron S, Quintela-Fandino M, Cominetti MR. (2021). [6]-Gingerol-Derived Semi-Synthetic Compound SSi6 Inhibits Tumor Growth and Metastatic Dissemination in Triple-Negative Breast Cancer Xenograft Models. Cancers 13, 2855. Publicación CNIO.
Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ. (2021). FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. Breast Cancer Res 23, 21. Publicación CNIO.
Bueno MJ, Ruiz-Sepulveda JL, Quintela-Fandino M (2021). Mitochondrial Inhibition: a Treatment Strategy in Cancer?. Curr Oncol Rep 23, 49. Publicación CNIO.
Mouron S, Bueno MJ, Muñoz M, Quintela-Fandino M. (2021). Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer. Oncoscience 8, 1-13. Publicación CNIO.
Quintela-Fandino M, Morales S, Cortés-Salgado A, Manso L, Apala JV, Muñoz M, Gasol Cudos A, Salla Fortuny J, Gion M, Lopez-Alonso A, Cortés J, Guerra J, Malón D, Caleiras E, Mulero F, Mouron S (2020). Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer.. Clin Cancer Res 26, 35-45. Publicación CNIO.
Moreno-Lama L, Galindo-Campos MA, Martínez C, Comerma L, Vazquez I, Vernet-Tomas M, Ampurdanés C, Lutfi N, Martin-Caballero J, Dantzer F, Quintela-Fandino M, Ali SO, Jimeno J, Yélamos J (2020). Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice. Oncogene 39, 2835-2843. Publicación CNIO.
Quintela-Fandino M, Holgado E, Manso L, Morales S, Bermejo B, Colomer R, Apala JV, Blanco R, Muñoz M, Caleiras E, Iranzo V, Martinez M, Dominguez O, Hornedo J, Gonzalez-Cortijo L, Cortes J, Gasol Cudos A, Malon D, Lopez-Alonso A, Moreno-Ortíz MC, Mouron S, Mañes S (2020). Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res 22, 124. Publicación CNIO. Open Access
Grunt TW, Slany A, Semkova M, Colomer R, López-Rodríguez ML, Wuczkowski M, Wagner R, Gerner C, Stübiger G (2020). Membrane disruption, but not metabolic rewiring, is the key mechanism of anticancer-action of FASN-inhibitors: a multi-omics analysis in ovarian cancer. Sci Rep 10, 14877. Publicación CNIO. Open Access
Bueno MJ, Quintela-Fandino MA (2020). Emerging role of Fatty acid synthase in tumor initiation: implications for cancer prevention.. MOLECULAR & CELLULAR ONCOLOGY 7, 1709389. Publicación CNIO.
Calvete O, Mouron S, Barroso A, Soberon N, Blasco MA , Quintela-Fandino M, Benítez J (2020). Long telomeres: A new prognostic factor for severity in triple-negative breast cancer patients. J Transl Sci (in press). Publicación CNIO.
Colomer R, Mondejar R, Romero-Laorden N, Alfranca A, Sanchez-Madrid F, Quintela-Fandino M (2020). When should we order a next generation sequencing test in a patient with cancer?. EClinicalMedicine 25, 100487. Publicación CNIO. Open Access
Bueno MJ, Jimenez-Renard V, Samino S, Capellades J, Junza A, López-Rodríguez ML, Garcia-Carceles J, Lopez-Fabuel I, Bolaños JP, Chandel NS, Yanes O, Colomer R, Quintela-Fandino M (2019). Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells.. Nat Commun 10, 5011. Publicación CNIO. Open Access
Morales ML, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodríguez-García A, Castro N, Zagorac I, Quintela-Fandino M, Gómez-López G, Gallardo M, Ayala R, Linares M, Martinez-Lopez J (2019). MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Sci Rep 9, 18630. Publicación CNIO. Open Access
Zagorac I, Fernandez-Gaitero S, Penning R, Post H, Bueno MJ, Mouron S, Manso L, Morente MM, Alonso S, Serra V, Muñoz J, Gómez-López G, Lopez-Acosta JF, Jimenez-Renard V, Gris-Oliver A, Al-Shahrour F, Piñeiro-Yañez E, Montoya-Suarez JL, Apala JV, Moreno-Torres A, Colomer R, Dopazo A, Heck AJR, Altelaar M, Quintela-Fandino M (2018). In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nat Commun 9, 3501. Publicación CNIO. Open Access
Álvarez-Fernández M, Sanz-Flores M, Sanz-Castillo B, Salazar-Roa M, Partida D, Zapatero-Solana E, Ali HR, Manchado E, Lowe S, VanArsdale T, Shields D, Caldas C, Quintela-Fandino M, Malumbres M (2018). Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Cell Death Differ 25, 828-840. Publicación CNIO.